Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies
Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 100237
DOI: 10.1016/j.bvth.2026.100237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Samer Salem und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Salem, S., McCrae, K. R., & Khorana, A. A. (2026). Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies. Blood Vessels, Thrombosis & Hemostasis, 100237. https://doi.org/10.1016/j.bvth.2026.100237
Vancouver
Salem S, McCrae KR, Khorana AA. Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies. Blood Vessels, Thrombosis & Hemostasis. 2026:100237. doi:10.1016/j.bvth.2026.100237
BibTeX
@article{Salem2026,
author = {Salem, Samer and McCrae, Keith R. and Khorana, Alok A.},
title = {Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
pages = {100237},
doi = {10.1016/j.bvth.2026.100237}
}
EUVIMED